Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DELTALIN vs CALCIPOTRIENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
Plaque psoriasis (FDA-approved),Psoriasis of the scalp (FDA-approved),Chronic plaque psoriasis (off-label),Psoriatic nails (off-label),Ichthyosis (off-label),Vitiligo (off-label)
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin.
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
No adjustment required due to minimal systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
No adjustment required due to minimal systemic absorption.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function.
None.
None.
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.,Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.,Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.,Use on face, groin, or axillae may increase irritation.,Not recommended in patients with known disorders of calcium metabolism.
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcipotriene or any component of the formulation,Use on face, eyes, or mucous membranes
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
No dose adjustment required for topical use as systemic absorption is minimal. However, limit use to small areas to minimize cumulative exposure. No pharmacokinetic studies in pregnancy indicate need for dose change.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
Apply a thin layer to affected areas only, avoiding healthy skin.,Wash hands after application unless treating hands.,Do not use on the face, groin, or skin folds unless specifically directed.,Do not exceed 100 grams per week to avoid side effects.,Avoid excessive sun exposure or tanning beds during treatment.,Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness.,Use exactly as prescribed; do not use occlusive dressings unless instructed.,May cause local skin irritation; report severe reactions to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DELTALIN vs CALCIPOTRIENE, answered by our medical review team.
DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. CALCIPOTRIENE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DELTALIN and CALCIPOTRIENE depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. The standard adult dose of CALCIPOTRIENE is: Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DELTALIN and CALCIPOTRIENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. CALCIPOTRIENE is classified as Category C. Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be rule. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.